Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 27, 2023
Daily News
February 27, 2023
- COVID-19 Drugs Haul Big Sales in 2022, Veklury Crosses 100 Billion Yen Line
February 27, 2023
- Pfizer Japan Files PARP Inhibitor Talazoparib for Breast and Prostate Cancer
February 27, 2023
- Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
- Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
- PMDA Reviewing 16 APIs for Paradoxical Drug Reaction
February 27, 2023
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…